Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128120 | 1.00 | KCNH2 (1.00) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1141460 | 0.99 | KCNH2 (0.98) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1141464 | 0.99 | KCNH2 (0.98) | KCNH2HRH3 | |
| SCHEMBL1939411 | 0.95 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1939700 | 0.95 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1938186 | 0.95 | KCNH2 (1.00) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1939603 | 0.94 | KCNH2 (0.98) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1939605 | 0.94 | KCNH2 (0.98) | KCNH2HRH3 | |
| Fumaric Acid SCHEMBL1141068 | 0.92 | KCNH2 (0.85) | KCNH2HRH3 | |
| Fumaric Acid SCHEMBL1141067 | 0.92 | KCNH2 (0.85) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | claimed |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | claimed |
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | disclosed |
| CN-102066319-A | Process for the synthesis of -1- {2- [ 4' - (3-methoxypropan-1-sulfonyl) -biphenyl-4-yl ] -ethyl } -2-methyl-pyrrolidine | ARENA PHARM INC | 2011-05-18 | — | — | CN | disclosed |
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2282992-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-Ý4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL¨-ETHYL}-2-METHYL-PYRROLIDINE | Arena Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2155668-A2 | CRYSTALLINE FORMS OF (R)-1-{2-Ý4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL¨-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155668-A2 | CRYSTALLINE FORMS OF (R)-1-{2-Ý4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL¨-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009128907-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-[4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009128907-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-[4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008153958-A3 | CRYSTALLINE FORMS OF (R)-1-{2-[4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARM INC (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008153958-A2 | CRYSTALLINE FORMS OF (R)-1-{2-[4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153958-A2 | CRYSTALLINE FORMS OF (R)-1-{2-[4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153958-A2 | CRYSTALLINE FORMS OF (R)-1-{2-[4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008048609-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | DHPS, MRM1, ALDH18A1 | KCNH2 2327/4885HRH3 2097/4885 |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | KCNH2 1344/4885HRH3 1/4885 |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | HRH3, HRH4, HTR1D | KCNH2 1455/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.